Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Tomoko Tachibana"'
Autor:
Mitsuhiro Shinada, Masashi Takahashi, Chika Igarashi, Hiroki Matsumoto, Fukiko Hihara, Tomoko Tachibana, Masakazu Oikawa, Hisashi Suzuki, Ming-Rong Zhang, Tatsuya Higashi, Hiroaki Kurihara, Yukie Yoshii, Yoshihiro Doi
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 820 (2024)
Copper (Cu) is a critical element for cancer cell proliferation and considerably accumulates in the nucleus. 64Cu2+ is an anticancer radiopharmaceutical that targets the copper requirement of cancer cells. However, intravenously injected 64Cu2+ ions
Externí odkaz:
https://doaj.org/article/2ec27f9bcaab4665b5ade683d11324ac
Autor:
Tomoko Tachibana, Tomoko Gowa Oyama, Yukie Yoshii, Fukiko Hihara, Chika Igarashi, Mitsuhiro Shinada, Hiroki Matsumoto, Tatsuya Higashi, Toshihiko Kishimoto, Mitsumasa Taguchi
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 24, p 17234 (2023)
Managing metastasis at the early stage and detecting and treating submillimeter tumors at early metastasis are crucial for improving cancer prognosis. Angiogenesis is a critical target for developing drugs to detect and inhibit submillimeter tumor gr
Externí odkaz:
https://doaj.org/article/11c3e5dfcac2430f9f99d0cd36bfbfbb
Autor:
Mitsuhiro Shinada, Hisashi Suzuki, Masayuki Hanyu, Chika Igarashi, Hiroki Matsumoto, Masashi Takahashi, Fukiko Hihara, Tomoko Tachibana, Chizuru Sogawa, Ming-Rong Zhang, Tatsuya Higashi, Hidemitsu Sato, Hiroaki Kurihara, Yukie Yoshii, Yoshihiro Doi
Publikováno v:
Pharmaceuticals, Vol 17, Iss 1, p 10 (2023)
[64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM) is a radioactive hypoxia-targeting therapeutic agent being investigated in clinical trials for malignant brain tumors. For the quality management of [64Cu]Cu-ATSM, understanding trace
Externí odkaz:
https://doaj.org/article/c8bb42d4b1ee4732af26836bf81048f1
Autor:
Yukie Yoshii, Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Kimiteru Ito, Tatsuya Higashi, Hiroaki Kurihara, Makoto Ueno
Publikováno v:
Pharmaceuticals, Vol 16, Iss 10, p 1341 (2023)
Understanding the physicochemical properties of antibody–drug conjugates is critical to assess their quality at manufacturing and monitor them during subsequent storage. For radiometal–antibody complexes, it is important to control the properties
Externí odkaz:
https://doaj.org/article/7b2fb5433caf4e8faa8f63f71d8cb5a2
Autor:
Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno, Kimiteru Ito, Tatsuya Higashi, Yukie Yoshii
Publikováno v:
Pharmaceutics, Vol 14, Iss 9, p 1928 (2022)
Detecting tumor lesions 64Cu-labeled anti-epidermal growth factor receptor (EGFR) antibody (64Cu-NCAB001 ipPET). Here, we conducted an extended single-dose toxicity study of 64Cu-NCAB001 ipPET in mice based on approach 1 of the current ICH M3 [R2] gu
Externí odkaz:
https://doaj.org/article/e8ac0a2197c1475b8a9f438d53777509
Autor:
Fukiko Hihara, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, Takashi Masuko, Yuichi Endo, Chika Igarashi, Tomoko Tachibana, Mitsuhiro Shinada, Ming-Rong Zhang, Gene Kurosawa, Aya Sugyo, Atsushi B. Tsuji, Tatsuya Higashi, Hiroaki Kurihara, Makoto Ueno, Yukie Yoshii
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 10, p 5807 (2022)
Peritoneal dissemination of pancreatic cancer has a poor prognosis. We have reported that intraperitoneal radioimmunotherapy using a 64Cu-labeled antibody (64Cu-ipRIT) is a promising adjuvant therapy option to prevent this complication. To achieve pe
Externí odkaz:
https://doaj.org/article/0d760c3e34b0475c92ee299e4da2927e
Autor:
Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Atsuo Waki, Ming-Rong Zhang, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno, Kimiteru Ito, Tatsuya Higashi, Yukie Yoshii
Publikováno v:
Pharmaceutics, Vol 14, Iss 1, p 67 (2021)
Early diagnosis of pancreatic cancer using current imaging modalities remains challenging. We have developed a new approach to identify tumor lesions ≥ 3 mm in the pancreas by positron emission tomography (PET) with a new intraperitoneally administ
Externí odkaz:
https://doaj.org/article/6a644441e22d458fbd7b4e0d9f7baf4e
Autor:
Mitsuyoshi Yoshimoto, Yukie Yoshii, Hiroki Matsumoto, Mitsuhiro Shinada, Masashi Takahashi, Chika Igarashi, Fukiko Hihara, Tomoko Tachibana, Ayano Doi, Tatsuya Higashi, Hirofumi Fujii, Kohshin Washiyama
Publikováno v:
Pharmaceutics, Vol 13, Iss 10, p 1706 (2021)
Actinium-225 (225Ac) is a promising radionuclide used in targeted alpha therapy (TAT). Although 225Ac labeling of bifunctional chelating ligands is effective, previous in vivo studies reported that free 225Ac can be released from the drugs and that s
Externí odkaz:
https://doaj.org/article/0469259c26574176ac2f6b94f2f08236
Autor:
Hiroki Matsumoto, Tadashi Watabe, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Atsuo Waki, Ming-Rong Zhang, Hideaki Tashima, Taiga Yamaya, Kazuhiro Ooe, Eku Shimosegawa, Jun Hatazawa, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno, Kimiteru Ito, Tatsuya Higashi, Yukie Yoshii
Publikováno v:
Pharmaceuticals, Vol 14, Iss 10, p 950 (2021)
Objectives: To improve the prognosis of pancreatic cancer, new imaging methods to identify tumor lesions at a size of 64Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called 64Cu-NCAB001 ipPET. Methods: NCA
Externí odkaz:
https://doaj.org/article/03f327a0c083423c9b177d4f28c40246
Autor:
Tomoko Tachibana, Tomoko Gowa Oyama, Yukie Yoshii, Fukiko Hihara, Chika Igarashi, Atsushi B Tsuji, Tatsuya Higashi, Mitsumasa Taguchi
Publikováno v:
Applied Sciences, Vol 11, Iss 15, p 7031 (2021)
Colorectal cancer is a frequent cause of death worldwide. The detection and treatment of small nodules are crucial for improving survival of colorectal cancer patients. Submillimeter tumors are useful tools for developing novel methods to approach th
Externí odkaz:
https://doaj.org/article/9706d927a1f34fddb34abe72ee272a80